alpha-aminopyridine has been researched along with idelalisib in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burger, JA | 1 |
| Wiestner, A | 1 |
| Fan, L; Han, TT; Li, JY; Xu, W | 1 |
| Niemann, CU | 1 |
| Pettitt, AR; Slupsky, JR; Till, KJ | 1 |
| Gray, JW | 1 |
| Grant, FM; Gyori, D; Hawkins, PT; Lim, EL; Okkenhaug, K; Roychoudhuri, R; Shuttleworth, SJ; Spensberger, D; Stephens, LR | 1 |
| Chen, WN; Jing, ZT; Lin, X; Lin, XJ; Liu, W; Wu, SX; Xue, CR | 1 |
4 review(s) available for alpha-aminopyridine and idelalisib
| Article | Year |
|---|---|
Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.
Topics: Adenine; Aminopyridines; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Morpholines; Oxazines; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Risk Factors; Signal Transduction | 2012 |
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.
Topics: Adenine; Aminopyridines; Antineoplastic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Medical Oncology; Morpholines; Mutation; NF-kappa B; Oxazines; Phosphatidylinositol 3-Kinases; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; src-Family Kinases | 2012 |
Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.
Topics: Aminopyridines; Antineoplastic Agents; Benzylamines; Chemokine CXCL12; Clinical Trials as Topic; Cyclams; Dasatinib; Heterocyclic Compounds; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Morpholines; Niacinamide; Oxazines; Phenylurea Compounds; Protein Kinase Inhibitors; Purines; Pyridines; Pyrimidines; Quinazolinones; Receptors, CXCR4; Sorafenib; Thalidomide; Thiazoles; Tumor Microenvironment | 2014 |
[Targeted treatment of chronic lymphocytic leukaemia].
Topics: Adenine; Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Morpholines; Oxazines; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; Sulfonamides | 2014 |
4 other study(ies) available for alpha-aminopyridine and idelalisib
| Article | Year |
|---|---|
Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents; B-Lymphocytes; Case-Control Studies; Cell Movement; Class I Phosphatidylinositol 3-Kinases; Gene Expression Regulation, Leukemic; Germinal Center; Human Umbilical Vein Endothelial Cells; Humans; Integrins; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Lysophospholipids; Morpholines; Oxazines; Piperidines; Primary Cell Culture; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Purines; Pyrazoles; Pyridines; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors; Syk Kinase | 2015 |
PI3 Kinase Pathway Mutations in Human Cancers.
Topics: Aminopyridines; Class I Phosphatidylinositol 3-Kinases; Humans; Isoquinolines; Molecular Targeted Therapy; Morpholines; Mutation; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Purines; Quinazolinones; Signal Transduction; Tumor Suppressor Protein p53 | 2016 |
Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.
Topics: Aminopyridines; Animals; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Diphtheria Toxin; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Forkhead Transcription Factors; Gene Knockout Techniques; Humans; Lymphocyte Depletion; Macrophages; Male; Mice; Mice, Transgenic; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Primary Cell Culture; Purines; Pyrroles; Quinazolinones; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; T-Lymphocytes, Regulatory; Tumor Microenvironment | 2018 |
PI3K/AKT inhibitors aggravate death receptor-mediated hepatocyte apoptosis and liver injury.
Topics: Aminopyridines; Animals; Antibodies; Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Chemical and Drug Induced Liver Injury; Hep G2 Cells; Hepatocytes; Humans; Imidazoles; Liver; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolinones; Tumor Necrosis Factor-alpha | 2019 |